Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

After the KFDA (Korea Food and Drug Administration) approval of a new drug, an annual report of the drug's safety and efficacy data must be reported to the Health Authority in 6 years. In this Observational study, we will investigate the basic demographic, medical history, concomitant drug use, as well as dosing information of multiple myeloma patients using bortezomib (Velcade).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Patients who are newly prescribed bortezomib injection for the treatment of multiple myeloma

Exclusion Criteria:

• Patients who are hypersensitive to the bortezomib or any component of the bortezomib or with a history of the hypersensitivity

• Patients with severe hepatic impairment

• Pregnant women